Puma Biotechnology, Inc.
PBYI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001401667
In the last 90 days, Puma Biotechnology, Inc. insiders filed 0 open-market purchases and 5 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $313.6M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Puma Biotechnology, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 93 | 99 | +6 |
| Shares | 29.7M | 31.0M | +1.23M (+4.1%) |
| Value | $157.7M | $100.9M | −$56.7M (−36.0%) |
New holders (26)
Institutions that held Puma Biotechnology, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (20)
Institutions that held Puma Biotechnology, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Camber Capital Management LP | 1,650,000 | $8.74M |
| Wellington Management Group LLP | 170,765 | $905.1K |
| Laurion Capital Management LP | 131,175 | $695.2K |
| HRT Financial LP | 127,231 | $674.0K |
| Cubist Systematic Strategies, LLC | 88,029 | $466.6K |
| EntryPoint Capital, LLC | 61,991 | $328.6K |
| Brevan Howard Capital Management LP | 49,875 | $264.3K |
| Jump Financial, LLC | 41,658 | $220.8K |
| Point72 Asia (Singapore) Pte. Ltd. | 38,346 | $203.2K |
| Crestline Management, LP | 35,832 | $189.9K |
| Balyasny Asset Management LLC | 32,709 | $173.4K |
| Y-Intercept (Hong Kong) Ltd | 19,383 | $102.7K |
| Omers Administration Corp | 16,800 | $89.0K |
| ExodusPoint Capital Management, LP | 15,627 | $83.0K |
| CTC Alternative Strategies, Ltd. | 12,100 | $64.1K |
| LMR Partners LLP | 11,006 | $58.3K |
| SG Americas Securities, LLC | 10,740 | $57.0K |
| Headlands Technologies LLC | 2,301 | $12.2K |
| Group One Trading, L.P. | 1,495 | $7.92K |
| GWM Advisors LLC | 717 | $3.80K |